FDA: Pregnant Women Should Avoid Valproate Drug for Migraine Prevention

The FDA warns against healthcare providers giving anti-seizure medications valproate sodium, valproic acid and divalproex sodium to pregnant women for migraine prevention, according to the American Society of Anesthesiologists.

Advertisement

FDA warns against valproate use for migraine prevention in pregnant womenA recent study showed these medicines caused lower IQ scores in children when mothers consumed them during pregnancy. Valproate’s pregnancy category will be changed from D, indicating potential benefit despite risks, to X, indicating risk outweighs any possible benefit, according to the report.

Valproate is approved to treat epilepsy, manic episodes associated with bipolar disorder and migraine headache prevention. Pregnant women should completely avoid it for migraines and should only use it for epilepsy or bipolar disorder if other treatments have failed.

More Articles on Anesthesia:
FDA Approves Sedasys Computer-Assisted System for GI Propofol Sedation
Masimo Rainbow Respiratory Monitor Cleared by FDA for Pediatric Use
Anesthesiologists Urge CMS, ONC to Continue Hardship Exemption Through MU Stage 3

Connecting Orthopedic Providers with Tools to Lead Impactful Financial Discussions with Patients

Recommended Live Webinar on Apr 24, 2025 12:00 PM - 1:00 PM CDT

Advertisement

Next Up in Anesthesia

  • Here are three health systems that have lost or cut ties with their anesthesia providers this year:  1. Des Moines,…

  • Des Moines, Iowa-based MercyOne Medical Center has ended its partnership with anesthesia services provider, Medical Center Anesthesiologists, according to a…

Advertisement

Comments are closed.